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Members of the Shank family of multidomain proteins (Shank1, Shank2, and Shank3) are
core components of the postsynaptic density (PSD) of excitatory synapses. At synaptic
sites Shanks serve as scaffolding molecules that cluster neurotransmitter receptors as
well as cell adhesion molecules attaching them to the actin cytoskeleton. In this study we
investigated the synapse specific localization of Shank1-3 and focused on well-defined
synaptic contacts within the hippocampal formation. We found that all three family
members are present only at VGLUT1-positive synapses, which is particularly visible at
mossy fiber contacts. No costaining was found at VGLUT2-positive contacts indicating
that the molecular organization of VGLUT2-associated PSDs diverges from classical
VGLUT1-positive excitatory contacts in the hippocampus. In light of SHANK mutations
in neuropsychiatric disorders, this study indicates which glutamatergic networks within
the hippocampus will be primarily affected by shankopathies.
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INTRODUCTION
The SHANK gene family comprises SHANK1, SHANK2, and SHANK3 and encodes for PSD-
associated scaffolding proteins at the excitatory synapse that interconnect neurotransmitter
receptors and cell adhesion molecules by direct and indirect interactions with numerous other
PSD-associated proteins (Sheng and Kim, 2000; Boeckers et al., 2002; Grabrucker et al., 2011b;
Sala et al., 2015). Several studies have shown that Shanks are important molecules for proper
excitatory synapse and circuit function (Peca et al., 2011; Schmeisser et al., 2012; Jiang and
Ehlers, 2013). Interestingly, mutations in SHANKS—especially in SHANK3 and SHANK2—have
been associated with neuropsychiatric disorders, in particular autism spectrum disorder (ASD)
(Leblond et al., 2014). In ASD, growing evidence points toward alterations in neuronal circuits
(Zikopoulos and Barbas, 2013; Gogolla et al., 2014; Rothwell et al., 2014) and ASD also appears
to be associated with a diminished interaction of the hippocampal and orbitofrontal systems
Abbreviations: ASD, autism spectrum disorders; CA1-4, Cornu Ammonis areas 1-4; DAPI, 4′,6-diamidino-2-phenylindole;
DG, dentate gyrus; EC, entorhinal cortex; IMF, intragranular mossy fibers; MAP2, microtubule-associated protein 2; MF,
mossy fibers; PBS, phosphate buffered saline; ProSAP, proline-rich synapse-associated protein, also known as Shank; PSD,
postsynaptic density; Shank, SH3 and multiple ankyrin repeat domains 3, also known as ProSAP; SPO, Synaptoporin also
known as Synaptophysin 2; SUM, supramammilary nucleus; Syn1/2, Synapsin1/2; VGLUT, vesicular glutamate transport.
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(Ameis et al., 2011). The reduced functional coupling represents
one of the possible underpinnings of abnormal socio-emotional
behavior observed in ASD patients since the hippocampus
modulates cortex-dependent behaviors by engaging in memory
retrieval relevant to the situation the organism is facing (Ramus
et al., 2007; Lehn et al., 2009; Pehrs et al., 2015). The
hippocampus receives input mainly from the entorhinal cortex
(EC) within the temporal lobe and processes the information
by relaying the signals within the trisynaptic circuit. The EC
projects via the perforant path to the stratum moleculare of
the dentate gyrus (DG) where dendritic spines of granule
cells receive the excitatory input. These cells then transduce
the excitatory input along mossy fibers (MFs) to the stratum
lucidum/stratum radiatum in CA3, where giantMF contacts exist
on large dendritic spines (also known as thorny excrescences)
of pyramidal cells. Of note, the axons of the granule cells
also form several large excitatory synaptic contacts with mossy
cells and other interneurons in the intragranular mossy fibers
(IMF), i.e., in regions of the MF proximal to the DG. CA3
pyramidal cells, in turn, project to the stratum radiatum in
CA1 via Schaffer collaterals where they form contacts with CA1
pyramidal cells which then project back to the EC via the
subiculum.
The vesicular glutamate transporters (VGLUTs) VGLUT1
and VGLUT2 are critical for excitatory signal transmission
(Fremeau et al., 2004; Wojcik et al., 2004) and in some
knock-out lines genetic deletion of VGLUT1 and VGLUT2
has resulted in premature death (Moechars et al., 2006;
Balschun et al., 2010). VGLUT3 is less clearly associated with
excitatory neurotransmission and rather functions at presynaptic
terminals of neurons mediating modulatory/monoaminergic
signals (Gras et al., 2002; Schafer et al., 2002; Amilhon
et al., 2010; Soiza-Reilly and Commons, 2011). Generally
speaking, VGLUT1, and VGLUT2 display a complementary
expression profile in the CNS of rodents and humans (Fremeau
et al., 2001, 2004; Varoqui et al., 2002; Commons et al.,
2005; Vigneault et al., 2015) and segregate input from
different brain regions. In the hippocampus, VGLUT1-
positive presynaptic terminals originate mainly from
neurons within the hippocampus itself and from the cortex
(Balschun et al., 2010; Zander et al., 2010), whereas the
origin of VGLUT2-positive presynaptic terminals is the
supramammillary nucleus (SUM) or mossy cells from other
regions of the hippocampus (Halasy et al., 2004; Boulland et al.,
2009).
Here we report that in the mouse hippocampus Shank1-
3 exclusively reside at VGLUT1-positive synapses—which is
particularly visible along the MFs—and not at VGLUT2-positive
synapses. Our data suggests that excitatory scaffolds can vary
significantly in their genetic makeup even within a single
brain region, and identifies the postsynapses of VGLUT2-
positive synapses as Shank-negative in the hippocampus.
Considering the strong link between genetic alterations of human
SHANK and neuropsychiatric disorders, our study suggests that
VGLUT1-dependent neuronal networks within the hippocampus
(e.g., the trisynaptic circuit) may be primarily affected by
shankopathies.
MATERIALS AND METHODS
Animal Ethics Statement
Shank2−/− and Shank3αβ−/− mice were previously described
(Schmeisser et al., 2012). All mice were kept in specific pathogen-
free animal facilities and all animal experiments in this study
were performed based on the guidelines for the welfare of
experimental animals issued by the Federal Government of
Germany and by the local ethics committee (Ulm University), ID
Number: 0.103.
Vector Constructs
Full length rat GFP-Shank1A was a kind gift of Dr. Carlo Sala and
has been previously described (Romorini et al., 2004). Full length
rat GFP-tagged Shank2 (Boeckers et al., 2005), full length human
mcherry-tagged GFP-Shank2 (Peykov et al., 2015), full length
rat GFP-Shank3a (Grabrucker et al., 2011a), and human GFP-
Shank3a (Cochoy et al., 2015) have been previously described, as
well.
Primary Antibodies
Primary antibodies used for immunocytochemistry were all
diluted 1:200, for western blotting a dilution of 1:500 was
used (except for actin which was diluted 1:100000). The
Shank2 (“ppI-SAM pabSA5192”) and Shank3 antibodies (“PRC
pab,” simply referred to as “Shank3” in the study and “C-
term/ProSAP2/Shank3”) have been characterized previously
(Bockers et al., 1999; Bockmann et al., 2002; Schmeisser et al.,
2012). The following primary antibodies were purchased
from commercial suppliers: Actin (Sigma-Aldrich Cat# A2228
RRID:AB_476697), Bassoon (Enzo Life Sciences Cat# ADI-
VAM-PS003-F RRID:AB_11181058), CTIP2 (Abcam Cat#
ab18465 RRID:AB_2064130) GAD65 (Abcam Cat# ab85866
RRID:AB_1860505), Homer 1b/c (Synaptic Systems GmbH
Cat# 160 023, no RRID yet), GluN1 (Sigma-Aldrich Cat#
G8913 RRID:AB_259978), Shank1 (Novus Cat# NB300-167
RRID:AB_2187584), SPO (Synaptic Systems GmbH Cat# 102
002 RRID:AB_887841), Syn1/2 (Synaptic Systems GmbH Cat#
160 003, no RRID yet), VGLUT1 (Synaptic Systems GmbH Cat#
135 304 RRID:AB_887878), VGLUT2 (Synaptic Systems GmbH
Cat# 135 404 RRID:AB_887884), and VGLUT 3 (Synaptic
Systems Cat# 135204, no RRID yet).
Secondary Antibodies
Secondary antibodies used in immunocytochemistry were all
coupled to Alexa Fluor R© 488, 568, or 647 (all from Life
Technologies, dilution 1:500). Secondary antibodies used for
western blotting were HRP-conjugated secondary antibodies
(Dako, Glostrup, Denmark, dilution 1: 1000).
Cell Culture
HEK293T were kept in DMEM at 37◦C in 5% CO2 as previously
described (Cochoy et al., 2015).
Transfection
HEK293T were transfected as previously described (Cochoy
et al., 2015).
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Section Preparation and
Immunohistochemistry
Animals were anesthesized (ketamine 100 mg/kg and Xylazin
16 mg/kg, solubilized in an NaCl solution) and perfused with
25ml cooled PBS and 50ml paraformaldehyde 4%. Then, brains
were left overnight in 4% paraformaldehyde, followed by an
incubation in 30% sucrose. Finally, brains were frozen in OCT
compound and put at −80◦C until the day before cryostat
sectioning. One day before sectioning, brains were put at −20◦C
to adapt to the cutting temperature (−22◦C) of the sectioning
procedure. 40 µm coronal sections were then made using a
cryostat (Leica CM3050 S) and appropriate microtome blades
(Feather, A35 Type). Sections were then transferred to PBS
without calcium and magensium (PBS−/−) for free floating
antibody labeling: Incubation with blocking solution (3% BSA
+ 0.3% Triton-X-100, diluted in PBS−/−) took place for 2 h
at RT on horizontal shaker. Then, sections were transferred
to wells containing the primary antibody (dilution 1:200 in
blocking solution) and incubation took place for 48 h at 4◦C
on horizontal shaker. 3 washes in PBS−/− (30 min at RT
on horizontal shaker) and the incubation with fluorophore
conjugated secondary antibodies (all coupled to Alexa Fluor R©
488, 568 or 647 (all from Life Technologies), dilution 1:500)
for 2 h at RT on horizontal shaker followed. Then, 3 washes
in PBS−/− (30 min at RT on horizontal shaker) followed and
mounting took place using mowiol containing diluted 4,6-
diamidino-2-phenylindole DAPI (dilution 1:50000). Images were
either captured using an upright fluorescence microscope (view
2.7.1 for details) and Axiovision software (Zeiss) for the 5X
overview images or using a confocal microscope (view 2.7.1
for details) using Zeiss proprietary software LSM5 the for the
close-up images. Image processing took place with ImageJ (US
National Institutes of Health). View “2.7.1 Image analysis and
image selection for immunocytochemical analysis” for further
details.
Image Analysis and Image Selection for
Immunocytochemical Analysis
Qualitative immunocytochemical analysis was carried out
on 5 male adult mice (age: 2 months). For quantitative
immunocytochemical analysis 5–8 images from these mice
were selected. At least 3 coronal sections were stained for
each antibody/antibody combination per animal to assure
representativeness of stainings. For confocal microscopy, an
LSM 710 microscope from Zeiss was used (objective Plan-
Apochromat 63x/1.40 Oil DIC M27; numeric aperture 1.40,
a pinhole setting which represents one airy disc was used;
used lasers had an excitation wavelength of 405 nm, 488,
561 and 633 nm with emission filters of 410–488 nm, 493–551
nm, 570–628 nm, and 638–747 nm, respectively). For confocal
microscopy, the acquisition depth in the z-axis was 3 µm at
acquisition intervals of 0.5 µm, i.e., 7 planes per coronal section.
Stainings were assessed plane by plane and representative 1
µm maximum projections were created using ImageJ. For wide
field microscopy pictures were taken with an upright Axioscope
microscope equipped with a Zeiss CCD camera (objective a
Plan-NEOFLUAR 5x/0.15 with NA 0.15; light source: ebq 100
isolated; filters: BP 515-565, BP 575-640, BP 690/50).
For quantitative immunocytochemical analysis of the Shank1-
3/VGLUT1-2 colocalization, two 63x images at acquisition
intervals of 0.5 µm were analyzed by the image software Imaris.
Analysis either pertained to entire 63x image (192.8 µm × 192.8
µm) or to a subfield (48.2 µm × 48.2 µm) within the 63x
image (view also Supplementary Figures 2, 2 and 2, 3). Puncta
were identified by Imaris using the “quality” parameter and
only puncta stringently conforming with the quality parameter
(bottom 10%) entered colocalization analysis. The center of mass
of the identified puncta was allowed a maximal distance of 0.7
µm. Statistical analysis was carried out using an ANOVA with a
post-hoc tukey test.
Biochemistry
HEK293T were transfected with full length rat GFP-Shank1A,
rat GFP-tagged Shank2, human mcherry-tagged GFP-Shank2,
rat GFP-Shank3a, human GFP-Shank3a, or appropriate empty
vectors. Lysis of transfected HEK293T was carried out in Triton
X-100 Lysis Buffer (150mM NaCl, 50mM Tris HCl, 1% Triton
X-100, pH 7.4, protease inhibitor mix from Roche).
Crude synaptosomal fractions frommouse hippocampus were
biochemically isolated as described previously (Schmeisser et al.,
2012). In brief, hippocampal tissue from male wildtype mice
was homogenized in HEPES-buffered sucrose (320mM sucrose,
5mM HEPES, pH 7.4) containing protease inhibitors (Roche).
Homogenates were centrifuged at 1000 g for 10 min at 4◦C to
pellet cell debris and nuclei. The pellet was discarded while the
supernatant was then centrifuged at 12,000 g for 20min at 4◦C
to yield the pelleted crude synaptosomal fraction which was then
solubilized in HEPES-buffered sucrose.
Both the HEK cell lysate and the crude synaptosomal
fractions from the hippocampus were then analyzed by
Bradford assay to assess protein concentration. Samples
were diluted by 4x loading dye (200 mM Tris-HCL, pH 6.8,
200 mM DTT, 4% SDS, 4mM EDTA, 40% glycerol, 0.02%
bromophenolblue) to a final concentration of 1 µg/µl. For
western blotting, equivalent amounts of protein were loaded
per lane (15 µg for HEK cell lysates and 25 µg for crude
synaptosomal fractions from mouse hippocampus). Western
blot analysis was carried out according to standard protocols.
HRP-conjugated secondary antibodies (Dako, Glostrup,
Denmark) were used in combination with the SuperSignal
detection system (Thermo Scientific) to visualize protein
bands.
RESULTS
Shank1-3 Distribution in the Mouse
Hippocampus Using Specific Antibodies
In this study we used target specific Shank antibodies which
have been extensively characterized in a recent work (Halbedl
et al., 2016) and were used in previous studies. For Shank1
we used NB300-167 from Novus (Schmeisser et al., 2012), for
Shank2 we used the “ppI-SAM pab SA5192” antibody (Bockers
et al., 1999; Schmeisser et al., 2012), for Shank3 we primarily
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used the “PRC pab” antibody (Schmeisser et al., 2012), and
in one case (Supplementary Figure S4) the “Shank3 (C-term)”
antibody (Bockmann et al., 2002) was used (Supplementary
Figure S1A). Initially, we expanded the specificity analysis of
the Shank 2 and Shank 3 antibodies for their target protein
at the level of western blotting and immunocytochemistry
using Shank overexpression and using hippocampal material
from Shank2−/− and Shank3αβ−/− mice. In immunoblot
analysis, the antibodies specifically recognize the protein at the
expected molecular weight (Supplementary Figures S1B,C,E).
More important for this study, immunocytochemical stainings of
the utilized antibodies reveal that they specifically recognize their
target protein in hippocampal sections (Supplementary Figure
S1D).
Shank1-3 Exhibit a
Synaptic/Somato-Synaptic Distribution in
the Hippocampus with a Prominent
Immunoreactivity in the Mossy Fibers
Wefirst analyzed the regional distribution of Shank1-3 in coronal
sections of the mouse hippocampus. Shank1 and 2 have a similar
distribution pattern as the classical excitatory synapse proteins
VGLUT1 (Figure 1, top box) and GluA1 (Supplementary Figures
S1, 2A) which exhibit low immunoreactivity in the somatic
layers while showing strong immunoreactivity in the synaptic
laminae (Balschun et al., 2010; Hagihara et al., 2011; Herzog et al.,
2011). Instead, Shank3 has a more somato-synaptic distribution,
exhibiting high immunoreactivity in the somatic layers while
showing moderate immunoreactivity in the synaptic laminae
(Figure 1). Interestingly, Shank3 shows a high immunoreactivity
in the IMFs in the polymorphic layer of the DG (Figure 1,
top box, green arrow; see also Figures 2, 3), which also
holds true for Shank1-2 upon closer inspection using confocal
microsopy (Figures 2, 3). Of note, all Shanks exhibit strong
immunoreactivity not only in the IMFs but in the entire MFs,
for example in the stratum radiatum/stratum lucidum of the CA3
(Figures 4, 5).
Synaptic Shank1-3 Are Colocalized with
VGLUT1 in the Dentate Gyrus, CA3, and
CA1
The global analysis of Shank1-3 immunostainings in the mouse
hippocampus reveals a clear co-distribution of the synaptic Shank
immunoreactivity with that of VGLUT1 (Figure 1, top box).
Upon closer inspection of the hippocampal subregions DG, CA3,
and CA1 using confocal microscopy it becomes apparent that
the synaptic Shank immunoreactivity is punctated (except for
stratum lucidum/stratum radiatum in CA3 where it takes on
a larger, arched appearance) and is co-localized with VGLUT1
and GluA1 (Figures 2, 4, 6; Supplementary Figures S2, 1–3, S4).
This co-localization is especially evident in the MF synapses
(Figures 2, 4), which can be identified by a colocalization of
VGLUT1 with Synaptoporin (SPO) (Supplementary Figures S1,
2C, S4), indicating MF boutons (Williams et al., 2011).
FIGURE 1 | Synaptic distribution of Shank1/2 and somato-synaptic
distribution of Shank3 in the mouse hippocampus, codistribution with
VGLUT1, no codistribution with VGLUT2. Top box: 5x magnification of
hippocampus. Immunofluorescence stainings of coronal sections from
wild-type mice probed with Shank1-3 (white; green in merge) and VGLUT1
(white; red in merge) antibodies; green arrow points toward the intragranular
mossy fibers where there is a prominent synaptic stain of Shank3; scale bar =
300 µm. Bottom box: same stainings as top box but with the VGLUT2
antibody (white; red in merge). Red arrow points toward the VGLUT2-band of
the DG; scale bar = 300 µm.
Synaptic Shank1-3 Do Not Colocalize with
VGLUT2 in the Dentate Gyrus or CA3
In contrast to VGLUT1, we observed that VGLUT2 (and
VGLUT3) have distribution patterns in the hippocampus which
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FIGURE 2 | Colocalization of Shank puncta with VGLUT1 puncta in the intragranular mossy fibers and the stratum moleculare of the dentate gyrus.
Top box: Schematic overview of hippocampus with enlarged region (yellow square; here: dentate Gyrus = DG, containing stratum granulare = SG, stratum
moleculare = SM, and polymorphic layer = PL; I. indicates uppermost row/figure in bottom box). Bottom box: confocal immunofluorescence stainings of coronal
sections from wild-type mice probed with the Shank1-3 (white; green in merge) and VGLUT1 (white; red in merge) antibodies. The upper rows (large squares) show
the enlarged region (3 = SM; 2 = SG; 1 = PL; scale bar = 100 µm), the bottom rows (small rectangles) show further enlargements (indicated in upper row by white
rectangles) in the PL (1, top row) and SM (3, bottom row) (scale bar = 5 µm).
do not follow that of a “classical” synaptic protein at the
excitatory synapse since a strong stain can be observed in somatic
laminae (Figure 1 bottom box; Supplementary Figures S1, 2B).
In fact, VGLUT2 shows its strongest immunoreactivity in the
outer part of the stratum granulare in the DG (Figure 1 bottom
box, red arrows; Figure 3) followed by a strong immunoreactivity
in the outer part of the stratum pyramidale in the CA3/CA2
(Figures 1, 5). These areas of strong VGLUT2 immunoreactivity
take on the appearance of bands (henceforth referred to as
“VGLUT2-bands”) and have been previously described (Halasy
et al., 2004; Boulland et al., 2009). Of note, there is only
a very low VGLUT2 signal in the CA1 subregion (Figure 1
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FIGURE 3 | No colocalization of Shank puncta with VGLUT2 puncta in the VGLUT2-band nor in the intragranular mossy fibers of the dentate gyrus.
Top box: Schematic overview of hippocampus with enlarged region (yellow square; here: dentate Gyrus = DG, containing stratum granulare = SG, stratum
moleculare = SM, and polymorphic layer = PL; I. indicates uppermost row/figure in bottom box). Bottom box: confocal immunofluorescence stainings of coronal
sections from wild-type mice probed with the Shank1-3 (white; green in merge), and VGLUT2 (white; red in merge) antibodies. The upper rows (large squares) show
the enlarged region (3 = SM; 2 = SG; 1 = PL; scale bar = 100 µm), the bottom rows (small rectangles) show further enlargements (indicated in upper row by white
rectangles) in the outer part of the SG (2, top row) and in the PL (1, bottom row) (scale bar = 5 µm). Red arrows indicate VGLUT2-band.
bottom box) which was not detectable by confocal imaging (data
not shown).
Interestingly, upon closer inspection of the DG and the
CA3 with confocal microscopy, we found that Shank1-
3 immunoreactivity is not colocalized with VGLUT2 (nor
VGLUT3), neither in the VGLUT2-bands nor in the MFs
(Figures 3,5; Supplementary Figures S3, 3, data for VGLUT3 is
only shown for DG; Supplementary Figures S2, 2, S2, 3). We
also costained VGLUT2 with the excitatory synapse molecule
Homer1b/c, with the inhibitory synapse molecules VGAT and
GAD65, and with Synapsin (Syn)1/2 and Bassoon which are both
localized at the excitatory and inhibitory presynapse (Richter
et al., 1999; Bragina et al., 2007).We found that VGLUT2-positive
synapses are colocalized with Syn1/2, partially colocalized with
Bassoon, and not colocalized with Homer 1b/c (Supplementary
Figures S3, 1, S5, 1). VGLUT2 is also colocalized with VGAT and
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FIGURE 4 | Colocalization of Shank immunoreactivity with VGLUT1 in the stratum radiatum/stratum lucidum of the CA3 region. Top box: Schematic
overview of hippocampus with enlarged region (yellow square; here: CA3 containing stratum pyramidale = SP, stratum oriens = SO and stratum radiatum = SR).
Bottom box: confocal immunofluorescence stainings of coronal sections from wild-type mice probed with the Shank1-3 (white; green in merge) and VGLUT1 (white;
red in merge) antibodies. The upper row (large squares) shows the enlarged region (3 = SO; 2 = SP; 1 = SR; scale bar = 100 µm), the bottom row (small rectangles)
shows a further enlargement (indicated in upper row by white rectangle) in the SR (scale bar = 5 µm).
partially colocalized with GAD65 in the VGLUT2-band of the
DG which also holds true for the VGLUT2-band in CA3 though
to a lesser degree. Of note, VGLUT2 puncta in the MFs exhibit
a lower degree of colocalization with VGAT and GAD65 than is
the case in the VGLUT2-bands (Supplementary Figures S3, 2, S5,
2). VGLUT3 only shows a partial colocalization with VGAT and
GAD65 and in the MFs this colocalization cannot be observed
(Supplementary Figures S3, 4).
DISCUSSION
To date, there has been no proper analysis of the detailed
synaptic distribution of Shanks in the hippocampus or other
ASD-associated brain regions, which is quite surprising given the
strong link between SHANK2 and especially SHANK3mutations,
ASD, and other neuropsychiatric disorders (Guilmatre et al.,
2014; Leblond et al., 2014). Therefore, we set out to analyse
the immunohistochemical localization of Shank1-3 in the mouse
hippocampus using specific antibodies and confocal microscopy.
Our macroscopic analysis revealed that Shank1-3 exhibit a
localization in synaptic hippocampal laminae but it is important
to point out that Shank3 also demonstrates a visible somatic
localization, suggesting additional roles of Shank3 in neurons
aside of its role as a scaffolding molecule at the PSD. Based
on our confocal microscopy data, we conclude that Shanks
do not uniformly reside at all excitatory postsynapses in the
hippocampus but rather form the postsynaptic scaffold at all
“classical,” VGLUT1-positive synapses, which is particularly
visible at synapses within the MFs. Instead, Shanks do not
participate in forming the postsynaptic scaffold at hippocampal
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FIGURE 5 | No colocalization of Shank immunoreactivity with VGLUT2 puncta in the VGLUT2-band of the stratum pyramidale nor in the mossy fibers
of the CA3. Top box: Schematic overview of hippocampus with enlarged region (yellow square; here: CA3 containing stratum pyramidale = SP, stratum oriens = SO
and stratum radiatum = SR). Bottom box: confocal immunofluorescence stainings of coronal sections from wild-type mice probed with the Shank1-3 (white; green in
merge) and VGLUT2 (white; red in merge) antibodies. The upper row (large squares) shows the enlarged region (3 = SO; 2 = SP; 1 = SR; scale bar = 100 µm), the
bottom row (small rectangles) shows further enlargements (indicated in upper row by white rectangles) in the lateral part of the SP (2, top row) and the SR (1, bottom
row) (scale bar = 5 µm). Red arrows indicate VGLUT2-band.
VGLUT2-positive synapses- neither in the somatically localized
VGLUT2-bands, nor in the MFs. This is surprising since it
has been described that other molecules specific for excitatory
synapses are present at these synaptic contacts and also at other
VGLUT2-positive synapses in various brain regions (Boulland
et al., 2009; Micheva et al., 2010; Soiza-Reilly and Commons,
2011). In line with previous work, we observed that VGLUT2
(and to a lesser degree VGLUT3) partially colocalizes with
molecules of the inhibitory synapse in the somatic layers of
the hippocampus (Herzog et al., 2004; Zander et al., 2010)
but interestingly our data also shows that a large fraction of
VGLUT2- (and especially VGLUT3-) positive synapses in the
MFs are probably not classical GABAergic synapses and, yet, do
not colocalize with Shanks.
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FIGURE 6 | Colocalization of Shank puncta with VGLUT1 puncta in the stratum radiatum of the CA1. Top box: Schematic overview of hippocampus with
enlarged region (yellow square; here: CA1 containing stratum pyramidale = SP, stratum oriens = SO and stratum radiatum = SR; I./II./III. indicates
uppermost/middle/bottom figure in bottom box). Bottom box: confocal immunofluorescence stainings of coronal sections from wild-type mice probed with the
Shank1-3 (white; green in merge) and VGLUT1 (white; red in merge) antibodies. The upper row (large squares) shows the enlarged region (3 = SO; 2 = SP; 1 = SR;
scale bar = 100 µm), the bottom row (small rectangles) shows a further enlargement (indicated in upper row by white rectangle) in the SR (scale bar = 5 µm).
Interestingly, the physiology of VGLUT2-positive synapses
differs from VGLUT1-positive synapses and, generally speaking,
VGLUT2-positive synapses have a higher probability of
transmitter release and display differences in synaptic plasticity
(Fremeau et al., 2004; Boulland et al., 2009; Weston et al., 2011).
Importantly, hippocampal VGLUT1- and VGLUT2-positive
presynaptic terminals originate from different populations of
neurons. VGLUT1-positive presynaptic terminals originate from
neuronal populations within the hippocampal formation/the
trisynaptic circuit (Figure 7) and from the cortex (Balschun
et al., 2010; Zander et al., 2010) and are therefore heavily
involved in processes like learning and memory, LTP-formation,
signal processing, socio-emotional behavior, memory retrieval
etc. (Shepherd, 1998; Balschun et al., 2010; Pehrs et al., 2015).
Instead, VGLUT2-positive presynaptic terminals originate
from the SUM or mossy cells situated along the ipsi- and
contralateral extension of the hippocampus (Halasy et al., 2004;
Boulland et al., 2009). Both the SUM and mossy cells have
functional relevance for the hippocampus. By modulating theta
rhythms, the SUM affects many processes in the hippocampus,
which include learning, REM sleep, and exploratory locomotor
activity (Kocsis and Vertes, 1994; Boulland et al., 2009).
Mossy cells, on the other hand, are “excitatory interneurons”
which receive inputs from granule cells via MF collaterals and
mediate their excitation back to granule cells or basket cells
along the ipsilateral extension of the hippocampus or to the
contralateral hippocampal formation. Therefore, mossy cells
may contribute to a “cross-talk” of trisynaptic circuits along
the ipsi- and contralateral extensions of the hippocampus
(Figure 7).
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FIGURE 7 | Schematic Overview of VGLUT1/Shank-positive and VGLUT2/Shank-negative synapses in the hippocampus. The hippocampus exhibits the
well characterized trisynaptic circuit with “classical” VGLUT1-positive synapses which utilize Shank1-3, and other PSD-associated molecules at the postsynapse.
Instead, VGLUT2 (and VGLUT3)-positive synapses are characterized by an absence of Shank molecules. VGLUT1- and VGLUT2-positive synapses have a
complementary distribution and segregate synaptic input from different brain regions for the hippocampus. Whereas VGLUT1-positive synapses are located in
non-somatic laminae throughout the hippocampus and mainly mediate input from the EC, VGLUT2-positive synapses are primarily located in the outer part of the
stratum granulare of the DG and the stratum pyramidale of the CA3/CA2 as “VGLUT2-bands” and mediate input from the SUM and mossy cells. The SUM affects
hippocampal function by modulating its theta rhythms, REM sleep etc. and mossy cells take part in the “crosstalk” between trisynaptic circuits along the ipsi- and
contralateral extension of the hippocampus.
Given our finding that Shanks are localized to hippocampal
VGLUT1- (but not VGLUT2-) positive synapses, one could
expect genetic alterations of SHANK2 or SHANK3 (like in ASD
and the Phelan-Mc-Dermid Syndrome) to have a particularly
strong effect on processes involving the trisynaptic circuit
if genetic buffering is insufficient (Bourgeron, 2015). For
example, learning and memory, memory retrieval, or the
proper exchange of information between the cortex and the
hippocampus may be disrupted, possibly contributing to the
abnormal socio-emotional behavior observed in ASD patients.
Instead, one may expect genetic alterations of SHANK2 or
SHANK3 to have less of an effect on VGLUT2-associated
circuits in the hippocampus and, therefore, shankopathies
may have a smaller impact on hippocampal theta rhythms,
REM sleep, and so forth. From this perspective our findings
may be viewed as part of an effort to better understand
the genetic underpinnings of neuropsychiatric disorders but
our investigation also contributes to the growing knowledge
that there is a large degree of heterogeneity among excitatory
synaptic contacts in the CNS in general (Rao et al., 1998;
O’Rourke et al., 2012).
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